EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Hybrid Mass Spectrometry Applied across the Production of Antibody Biotherapeutics

Emilia Christofi, Mark O'Hanlon, Robin Curtis iD, Arghya Barman, Jeff Keen, Tibor Nagy, Perdita Barran iD

Journal of the American Society for Mass Spectrometry · 2025

DOI: 10.1021/jasms.4c00253 ↗

At a glance

Journal article in Journal of the American Society for Mass Spectrometry, 2025. Written by Emilia Christofi and 6 co-authors. Institution: Michael Barber Centre for Collaborative Mass Spectrometry, MBCCMS, Princess Street, Manchester M17DN, U.K. Major MEDLINE topics: Trastuzumab, Antibodies, Monoclonal, Mass Spectrometry, Immunoglobulin G. Cited 1 times so far (Crossref); 108 references. The full text is freely available (open access, CC BY 4.0). Funded by: Engineering and Physical Sciences Research Council, Waters Corporation.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Post expression from the host cells, biotherapeutics undergo downstream processing steps before final formulation. Mass spectrometry and biophysical characterization methods are valuable for examining conformational and stoichiometric changes at these stages, although typically not used in biomanufacturing, where stability is assessed via bulk property studies. Here we apply hybrid MS methods to understand how solution condition changes impact the structural integrity of a biopharmaceutical across the processing pipeline. As an exemplar product, we use the model IgG1 antibody, mAb4. Flexibility, stability, aggregation propensity, and bulk properties are evaluated in relation to perfusion media, purification stages, and formulation solutions. Comparisons with Herceptin, an extensively studied IgG1 antibody, were conducted in a mass spectrometry-compatible solution. Despite presenting similar charge state distributions (CSD) in native MS, mAb4, and Herceptin show distinct unfolding patterns in activated ion mobility mass spectrometry (aIM-MS) and differential scanning fluorimetry (DSF). Herceptin's greater structural stability and aggregation onset temperature (Tagg) are attributed to heavier glycosylation and kappa-class light chains, unlike the lambda-class light chains in mAb4. Hydrogen-deuterium exchange mass spectrometry (HDX-MS) revealed that mAb4 undergoes substantial structural changes during purification, marked by high flexibility, low melting temperature (Tm), and prevalent repulsive protein-protein interactions but transitions to a compact and stable structure in high-salt and formulated environments. Notably, in formulation, the third constant domain (CH3) of the heavy chain retains flexibility and is a region of interest for aggregation. Future work could translate features of interest from comprehensive studies like this to targeted approaches that could be utilized early in the development stage to aid in decision-making regarding targeted mutations or to guide the design space of bioprocesses and formulation choices.

Subjects

MeSH terms (MEDLINE)

TrastuzumabAntibodies, MonoclonalMass SpectrometryImmunoglobulin GCricetulusAnimalsCHO CellsHydrogen Deuterium Exchange-Mass SpectrometryProtein StabilityHumansIon Mobility SpectrometryGlycosylation

Substances

TrastuzumabAntibodies, MonoclonalImmunoglobulin G

Authors and institutions

  • Michael Barber Centre for Collaborative Mass Spectrometry, MBCCMS, Princess Street, Manchester M17DN, U.K.
  • Manchester Institute of Biotechnology, University of Manchester, Princess Street, Manchester M17DN, U.K.
  • FUJIFILM Diosynth Biotechnologies, Belasis Ave, Stockton-on-Tees, Billingham TS23 1LH, U.K.

ORCID profiles: Robin Curtis, Perdita Barran

Funding

  • Engineering and Physical Sciences Research Council
  • Waters Corporation

Cite

APA

Christofi, E., O'Hanlon, M., Curtis, R., Barman, A., Keen, J., Nagy, T., & Barran, P. (2025). Hybrid Mass Spectrometry Applied across the Production of Antibody Biotherapeutics. Journal of the American Society for Mass Spectrometry. https://doi.org/10.1021/jasms.4c00253

Vancouver

Christofi E, O'Hanlon M, Curtis R, Barman A, Keen J, Nagy T, et al. Hybrid Mass Spectrometry Applied across the Production of Antibody Biotherapeutics. Journal of the American Society for Mass Spectrometry. 2025. doi:10.1021/jasms.4c00253

BibTeX
@article{Christofi2025,
  author = {Christofi, Emilia and O'Hanlon, Mark and Curtis, Robin and Barman, Arghya and Keen, Jeff and Nagy, Tibor and Barran, Perdita},
  title = {Hybrid Mass Spectrometry Applied across the Production of Antibody Biotherapeutics},
  journal = {Journal of the American Society for Mass Spectrometry},
  year = {2025},
  doi = {10.1021/jasms.4c00253}
}
Start for free →